Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.3K
Overview
44.3K
Cross-reactivity00:42

Cross-reactivity

31.0K
Overview
31.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosing Congenital Sucrase-Isomaltase Deficiency in Children: An Algorithm Using Combined Breath Testing.

Pediatric gastroenterology, hepatology & nutrition·2026
Same author

Defining the Contribution of Genetic Variants in MRGPRX4 With Pruritus in Paediatric Cholestasis: Evidence From Case-Control Study.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Navigating Epstein-Barr Virus (EBV) and Post-Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Liver Transplantation: Current Knowledge and Strategies for Treatment and Surveillance.

Viruses·2025
Same author

Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD): Trends, Mortality, and Socioeconomic Disparities in the U.S., 1998-2020.

Children (Basel, Switzerland)·2025
Same author

Non-Invasive Biomarkers and Breath Tests for Diagnosis and Monitoring of Chronic Liver Diseases.

Diagnostics (Basel, Switzerland)·2025
Same author

Use of Hepatitis C Viremic Donors to Expand the Pediatric Donor Pool.

Pathogens (Basel, Switzerland)·2024
Same journal

Correction: Fukushima et al. Long-Term Immunogenicity of Rabies Pre-Exposure Prophylaxis in Japanese Adult Travelers: Comparison of Dosing Regimens. <i>Vaccines</i> 2025, <i>13</i>, 1169.

Vaccines·2026
Same journal

Access to Vaccines Among Asylum Seekers, Refugees, and Undocumented Migrants Across the Migratory Cycle in the European Union, European Economic Area, Switzerland and the United Kingdom: A Scoping Review.

Vaccines·2026
Same journal

Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies.

Vaccines·2026
Same journal

Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).

Vaccines·2026
Same journal

Post-Marketing Safety Surveillance of Influenza Vaccines in Anhui Province, China, 2016-2025.

Vaccines·2026
Same journal

Characteristics of Hypotonic-Hyporesponsive Episodes (HHEs) Following Childhood Vaccination: A 13-Year Analysis of Spontaneous Reports to the Dutch Pharmacovigilance Centre Lareb.

Vaccines·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.7K

Hepatitis E Vaccines Updates.

Christopher Hartley1, Paul Wasuwanich2, Trung Van3

  • 1The Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD 21287, USA.

Vaccines
|July 27, 2024
PubMed
Summary
This summary is machine-generated.

Developing a hepatitis E vaccine is crucial due to the virus's prevalence. This vaccine is especially important for protecting pregnant individuals and immunocompromised populations from severe complications.

Keywords:
clinical trial reviewemerging vaccineshepatitis E

More Related Videos

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

6.9K
An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

35.9K

Related Experiment Videos

Last Updated: Jun 18, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.7K
Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

6.9K
An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

35.9K

Area of Science:

  • Virology
  • Vaccinology
  • Public Health

Background:

  • Hepatitis E virus (HEV) infection, while often self-limiting, presents significant risks to pregnant and immunocompromised individuals.
  • High prevalence of HEV necessitates targeted preventive strategies, particularly for vulnerable demographics.

Purpose of the Study:

  • To review the historical development of hepatitis E vaccines.
  • To explore the potential impact of a hepatitis E vaccine on at-risk populations.
  • To underscore the critical need for a vaccine to safeguard public health.

Main Methods:

  • Literature review of historical hepatitis E vaccine development efforts.
  • Analysis of the disease's impact on pregnant and immunocompromised individuals.
  • Examination of milestones in vaccine research and formulation.

Main Results:

  • Historical efforts have focused on mitigating HEV disease severity, especially in endemic regions.
  • Vulnerable groups, including pregnant women and the immunocompromised, face severe complications from HEV infection.
  • The need for a vaccine is amplified when considering these high-risk demographics.

Conclusions:

  • A hepatitis E vaccine is imperative for protecting vulnerable populations and the general public.
  • Understanding the vaccine's development journey provides insights into its public health benefits.
  • Informed public health strategies are essential for effectively combating hepatitis E.